Maze Therapeutics (NASDAQ:MAZE) Reaches New 1-Year High on Analyst Upgrade

Maze Therapeutics, Inc. (NASDAQ:MAZE) hit a new 52-week high on Friday after HC Wainwright raised their price target on the stock from $34.00 to $50.00. HC Wainwright currently has a buy rating on the stock. Maze Therapeutics traded as high as $25.50 and last traded at $24.80, with a volume of 5074476 shares changing hands. The stock had previously closed at $16.02.

MAZE has been the subject of a number of other research reports. Wedbush assumed coverage on Maze Therapeutics in a research report on Tuesday, July 8th. They set an “outperform” rating and a $17.00 price objective for the company. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Finally, BTIG Research boosted their price target on Maze Therapeutics from $30.00 to $37.00 and gave the stock a “buy” rating in a research report on Friday. Two research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $30.17.

Institutional Trading of Maze Therapeutics

Several institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC lifted its holdings in shares of Maze Therapeutics by 452.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company’s stock valued at $57,000 after buying an additional 3,774 shares during the period. Frazier Life Sciences Management L.P. lifted its holdings in shares of Maze Therapeutics by 10.6% in the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock valued at $56,040,000 after buying an additional 438,274 shares during the period. Engineers Gate Manager LP acquired a new stake in shares of Maze Therapeutics in the second quarter valued at $125,000. Bank of America Corp DE lifted its holdings in shares of Maze Therapeutics by 33.6% in the second quarter. Bank of America Corp DE now owns 5,782 shares of the company’s stock valued at $71,000 after buying an additional 1,455 shares during the period. Finally, CW Advisors LLC acquired a new stake in shares of Maze Therapeutics in the second quarter valued at $371,000.

Maze Therapeutics Stock Down 6.0%

The company has a fifty day moving average price of $15.28 and a two-hundred day moving average price of $12.28.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.02.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.